ASCO 2019 - Chicago - Chronic Myeloid Leukemia
GENERAL INFORMATION
ASCO American Society of Clinical Oncology - May 31 - June 4, 2019 - McCormick Place, Chicago, Illinois
NEWS
Efficacy of Bosutinib in Chronic Myeloid Leukemia Resistant to Prior Treatment
June 5, 2019, Hematology Advisor
Treatment-Free Remission After Nilotinib May Be Durable in Chronic Myeloid Leukemia
June 3, 2019, Hematology Advisor
Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia
June 2, 2019, Cancer Therapy Advisor
Flumatinib Superior to Imatinib in Chronic Myeloid Leukemia
June 1, 2019, ASH Clinicals News
VIDEOS
coming soon
coming soon
SOME INTERESTING ABSTRACTS ABOUT CML
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL)
Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study
Molecular prediction of chronic myeloid leukemia risk and resistance to imatinib
Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study
Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP)
Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial
A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)
Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML)
Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP)
Outcome of CML patients with de novo bleeding complications: Do they behave differently?
CML patients presenting with priapism: Is there any disparity in outcome?
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL)
Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study
Molecular prediction of chronic myeloid leukemia risk and resistance to imatinib
Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study
Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP)
Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial
A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)
Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML)
Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP)
Outcome of CML patients with de novo bleeding complications: Do they behave differently?
CML patients presenting with priapism: Is there any disparity in outcome?